NCT07344922CompletedPhase 3
SGLT2 Inhibitors in Non-Diabetic CKD: Effects on Vascular Calcification and Anemia
Impact of Sodium-Glucose Co-transporter 2 Inhibitors on Cardiovascular System and Anemia in Non-diabetic Chronic Kidney Disease Patients. A Randomized-Controlled Clinical Trial
Source: ClinicalTrials.gov · Last updated 15 Jan 2026
Brief summary (registry, in English)
The goal of this clinical trial is to learn if the drug dapagliflozin (an SGLT2 inhibitor) can help protect the kidneys, improve anemia, and support heart health in adults with chronic kidney disease (CKD) who do not have diabetes. The main questions it aims to answer are: Does dapagliflozin slow the worsening of kidney function compared to standard care? Does dapagliflozin improve anemia by increasing hemoglobin and related blood markers? Does dapagliflozin improve heart function and reduce cardiovascular problems in CKD patients? Researchers will compare dapagliflozin to a placebo (a look-alike pill with no active drug) to see if dapagliflozin works better than standard treatment alone. Participants will: Take dapagliflozin or a placebo once daily for 12 months, along with their usual CKD medications. Visit the clinic every 3 months for checkups, blood tests, urine tests, and heart evaluations. Have measurements of kidney function, anemia markers, and heart health taken at baseline and during follow-up visits.
- Status (registry)
- Completed
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 100 (actual)
- First submitted
- 14 Dec 2025
- Start date
- Sept 2022
- Primary completion date
- Nov 2023
- Lead sponsor
- Mansoura University
- Diseases
- Chronic kidney disease
- NCT number
- NCT07344922
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 100
- From Sept 2022 to the primary completion date, Nov 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- History of kidney transplantation or currently on dialysis.
Other illness
- Diagnosis of diabetes mellitus (type 1 or type 2).
- Known hypersensitivity to dapagliflozin or excipients.
- Severe uncontrolled cardiovascular disease (e.g., recent myocardial infarction, unstable angina, decompensated heart failure).
- Any condition judged by the investigator to interfere with study participation or interpretation of results.
Other
- Acute kidney injury within the past 3 months.
- Pregnant or breastfeeding women.
- Participation in another interventional clinical trial within the past 30 days.
Who the study is looking for
- Adults aged ≥18 years with a diagnosis of chronic kidney disease (CKD), non-diabetic etiology.
- Estimated glomerular filtration rate (eGFR) between 20 and 60 mL/min/1.73 m² at screening.
- Stable standard CKD care for at least 3 months prior to enrollment.
- Ability to provide written informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Urology and Nephrology Center, Mansoura University Coordinator of this site? Confirm its status | Al Mansurah | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.